175 related articles for article (PubMed ID: 1530976)
1. The biochemistry and pharmacology of PD 116124 (8-amino-2'-nordeoxyguanosine), an inhibitor of purine nucleoside phosphorylase (PNP).
Dong MK; Scott ME; Schrier DJ; Suto MJ; Sircar JC; Black A; Chang T; Gilbertsen RB
J Pharmacol Exp Ther; 1992 Jan; 260(1):319-26. PubMed ID: 1530976
[TBL] [Abstract][Full Text] [Related]
2. Biochemical and pharmacological properties of CI-972, a novel 9-deazaguanine analog purine nucleoside phosphorylase (PNP) inhibitor.
Gilbertsen RB; Dong MK; Wilburn DJ; Kossarek LM; Sircar JC; Kostlan CR; Conroy MC
Adv Exp Med Biol; 1991; 309A():41-4. PubMed ID: 1789255
[TBL] [Abstract][Full Text] [Related]
3. Preliminary report on 8-amino-9-(2-thienylmethyl)guanine (PD 119,229), a novel and potent purine nucleoside phosphorylase inhibitor.
Gilbertsen RB; Scott ME; Dong MK; Kossarek LM; Bennett MK; Schrier DJ; Sircar JC
Agents Actions; 1987 Aug; 21(3-4):272-4. PubMed ID: 3120507
[TBL] [Abstract][Full Text] [Related]
4. Comparative in vitro and in vivo activities of two 9-deazaguanine analog inhibitors of purine nucleoside phosphorylase, CI-972 and PD 141955.
Gilbertsen RB; Josyula U; Sircar JC; Dong MK; Wu WS; Wilburn DJ; Conroy MC
Biochem Pharmacol; 1992 Sep; 44(5):996-9. PubMed ID: 1530667
[TBL] [Abstract][Full Text] [Related]
5. Potent orally bioavailable purine nucleoside phosphorylase inhibitor BCX-4208 induces apoptosis in B- and T-lymphocytes--a novel treatment approach for autoimmune diseases, organ transplantation and hematologic malignancies.
Bantia S; Parker C; Upshaw R; Cunningham A; Kotian P; Kilpatrick JM; Morris P; Chand P; Babu YS
Int Immunopharmacol; 2010 Jul; 10(7):784-90. PubMed ID: 20399911
[TBL] [Abstract][Full Text] [Related]
6. Selective in vitro inhibition of human MOLT-4 T lymphoblasts by the novel purine nucleoside phosphorylase inhibitor, CI-972.
Gilbertsen RB; Dong MK; Kossarek LM; Sircar JC; Kostlan CR; Conroy MC
Biochem Biophys Res Commun; 1991 Aug; 178(3):1351-8. PubMed ID: 1908235
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of deoxyguanosine lymphotoxicity. Human thymocytes, but not peripheral blood lymphocytes accumulate deoxy-GTP in conditions simulating purine nucleoside phosphorylase deficiency.
Fairbanks LD; Taddeo A; Duley JA; Simmonds HA
J Immunol; 1990 Jan; 144(2):485-91. PubMed ID: 2104895
[TBL] [Abstract][Full Text] [Related]
8. Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)--a novel potent and orally active immunosuppressive agent.
Bantia S; Miller PJ; Parker CD; Ananth SL; Horn LL; Kilpatrick JM; Morris PE; Hutchison TL; Montgomery JA; Sandhu JS
Int Immunopharmacol; 2001 Jun; 1(6):1199-210. PubMed ID: 11407314
[TBL] [Abstract][Full Text] [Related]
9. Decreased methionine synthesis in purine nucleoside-treated T and B lymphoblasts and reversal by homocysteine.
Boss GR; Pilz RB
J Clin Invest; 1984 Oct; 74(4):1262-8. PubMed ID: 6332827
[TBL] [Abstract][Full Text] [Related]
10. Effect of 9-benzyl-9-deazaguanine, a potent inhibitor of purine nucleoside phosphorylase, on the cytotoxicity and metabolism of 6-thio-2'-deoxyguanosine.
Parker WB; Allan PW; Niwas S; Montgomery JA; Bennett LL
Cancer Res; 1994 Apr; 54(7):1742-5. PubMed ID: 8137289
[TBL] [Abstract][Full Text] [Related]
11. Functional and mechanistic studies on the toxicity of deoxyguanosine for the in vitro proliferation and differentiation of human peripheral blood B lymphocytes.
Scharenberg JG; Spaapen LJ; Rijkers GT; Duran M; Staal GE; Zegers BJ
Eur J Immunol; 1986 Apr; 16(4):381-7. PubMed ID: 3084280
[TBL] [Abstract][Full Text] [Related]
12. 8-Amino-9-substituted guanines: potent purine nucleoside phosphorylase (PNP) inhibitors.
Sircar JC; Kostlan CR; Pinter GW; Suto MJ; Bobovski TP; Capiris T; Schwender CF; Dong MK; Scott ME; Bennett MK
Agents Actions; 1987 Aug; 21(3-4):253-6. PubMed ID: 3120506
[TBL] [Abstract][Full Text] [Related]
13. 2'-deoxyguanosine toxicity for B and mature T lymphoid cell lines is mediated by guanine ribonucleotide accumulation.
Sidi Y; Mitchell BS
J Clin Invest; 1984 Nov; 74(5):1640-8. PubMed ID: 6334099
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology and mechanism of action of forodesine, a T-cell targeted agent.
Gandhi V; Balakrishnan K
Semin Oncol; 2007 Dec; 34(6 Suppl 5):S8-12. PubMed ID: 18086347
[TBL] [Abstract][Full Text] [Related]
15. A purine nucleoside phosphorylase (PNP) inhibitor induces apoptosis via caspase-3-like protease activity in MOLT-4 T cells.
Posmantur R; Wang KK; Nath R; Gilbertsen RB
Immunopharmacology; 1997 Oct; 37(2-3):231-44. PubMed ID: 9403342
[TBL] [Abstract][Full Text] [Related]
16. A rat model of purine nucleoside phosphorylase deficiency.
Osborne WR; Barton RW
Immunology; 1986 Sep; 59(1):63-7. PubMed ID: 3019875
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of purine nucleoside phosphorylase by 8-aminoguanosine: selective toxicity for T lymphoblasts.
Kazmers IS; Mitchell BS; Dadonna PE; Wotring LL; Townsend LB; Kelley WN
Science; 1981 Dec; 214(4525):1137-9. PubMed ID: 6795718
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of 2'-deoxyguanosine toxicity in mouse T-lymphoma cells with purine nucleoside phosphorylase deficiency and resistance to inhibition of ribonucleotide reductase by dGTP.
Duan DS; Nagashima T; Hoshino T; Waldman F; Pawlak K; Sadee W
Biochem J; 1990 Jun; 268(3):725-31. PubMed ID: 2114100
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor--BCX-1777.
Bantia S; Ananth SL; Parker CD; Horn LL; Upshaw R
Int Immunopharmacol; 2003 Jun; 3(6):879-87. PubMed ID: 12781704
[TBL] [Abstract][Full Text] [Related]
20. Effect of immunosuppressive agents on human T and B lymphoblasts.
Kazmers IS; Daddona PE; Dalke AP; Kelley WN
Biochem Pharmacol; 1983 Mar; 32(5):805-10. PubMed ID: 6404281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
